Ousia Pharma ApS
APSActiveCVR 43055909Ole Maaløes Vej 3, 2200 København NResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2022 · 4 years old8 employees
Loading company…
Overview
Ousia Pharma ApS is a Danish APS based in København N, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2022, the company has 8 employees and reported a gross profit of -DKK 10.2m in its latest annual filing.
Gross profit 2025
-10.2M DKK
+179% vs 2024
EBITDA margin (of gross profit)
141.2 %
−154% vs 2024
Net profit 2025
-12.8M DKK
-139% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
94.6 %
Very strongAmong the 20% highest rated companies in the industry
20222025
Liquidity ratioCurrent assets ÷ Short-term debt
18.4×
Very strongAmong the 20% highest rated companies in the industry
20222025
Return on assets (ROA)Net profit ÷ Total assets × 100
-102.2 %
Very weakAmong the 10% lowest rated companies in the industry
20222025
EBITDA — year on year
DKK millionsKey figures
Annual report 2025| Gross profit | -10.2M DKK | +179% |
| EBITDA | -14.4M DKK | -154% |
| Net profit | -12.8M DKK | -139% |
| Total assets | 12.5M DKK | +146% |
| Equity | 11.8M DKK | +217% |
| Employees | 8 | — |
Company information
Legal name
Ousia Pharma ApS
CVR number
43055909
Legal form
Anpartsselskab
Founded
14 February 2022 · 4 years
Share capital
DKK 99,583
Employees
8 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden sammen med to bestyrelsesmedlemmer eller af den samlede bestyrelse i forening.
Company purpose
Formål er at udvikle nye lægemiddelkandidater til behandling af kroniske sygdomme.
(no translation available)
Address
Ole Maaløes Vej 3, 2200 København N
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Ousia Pharma ApS reported a gross profit of -DKK 10.2m. The figures on this page draw on 4 annual filings covering 2022 to 2025. The bottom line showed a net loss of DKK 12.8m.
At the end of 2025, equity financed 94.6% of the balance sheet, and current assets covered short-term debt 18.4 times. Ousia Pharma ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.
Financials
Gross profit
DKK millionsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross profit | -10,205 | -3,656 | -2,240 | -645 |
| Staff expenses | -4,209 | -2,016 | -2,064 | -450 |
| EBITDA | -14,414 | -5,672 | -4,304 | -1,095 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -14,414 | -5,672 | -4,304 | -1,095 |
| Net financials | -448 | -510 | -232 | -110 |
| Profit before tax | -14,862 | -6,181 | -4,536 | -1,205 |
| Tax | -2,084 | -833 | -789 | -301 |
| Net profit | -12,778 | -5,349 | -3,747 | -904 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | 12,498 | 5,090 | 5,798 | 3,280 |
| Equity | 11,818 | -10,087 | -4,738 | -864 |
| Long-term debt | 0 | 10,841 | 10,314 | 4,090 |
| Short-term debt | 680 | 4,336 | 223 | 54 |
| Total debt | 680 | 15,177 | 10,537 | 4,144 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20222025
Equity ratio
94.6 %
Very strongAmong the 20% highest rated companies in the industry
20222025
Return on equity
-108.1 %
Very weakAmong the 10% lowest rated companies in the industry
20222025
Net profit margin (of gross profit)
<−999 %
20222025
Asset turnover (of gross profit)
-0.82×
20222025
Debt / equity
0.06×
Very strongAmong the 20% highest rated companies in the industry
20222025
Sector performance
22 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 10% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current ratioVery strong
Among the 20% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 20% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 10% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 40% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 20% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 20% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 20% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 20% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 20% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 20% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalVery strong
Among the 10% highest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in debtVery strong
Among the 10% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's equity.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-02-14 – 2022-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
CC Management | Management | 2022 |
JO Management | Management | 2022 |
AB Management | Management | 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
OS Board of Directors | Board of Directors | 2025 |
MN Board of Directors | Board of Directors | 2025 |
RR Board of Directors | Board of Directors | 2026 |
GG Chairman | Chairman | 2026 |
Former (8)
MS Board of Directors | Board of Directors | 2023 – 2025 |
IR Chairman | Chairman | 2023 – 2026 |
CC Board of Directors | Board of Directors | 2023 – 2026 |
JO Board of Directors | Board of Directors | 2023 – 2025 |
ME Board of Directors | Board of Directors | 2025 – 2026 |
MP Board of Directors | Board of Directors | 2023 – 2025 |
JR Board of Directors | Board of Directors | 2023 – 2025 |
AB Board of Directors | Board of Directors | 2023 – 2025 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
JLSa2 Therapeutics, Inc. | Company | 100% | 100% | 2026 |
| Individual | 33.33–49.99% | 33.33% | 2026 | |
| Company | 10–14.99% | 10–14.99% | 2025 | |
| Company | 10–14.99% | 10% | 2026 | |
| Company | 10–14.99% | 10% | 2026 | |
| Company | 5–9.99% | 5% | 2026 | |
| Company | 10–14.99% | 10% | 2026 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
JLSa2 Therapeutics, Inc.100%
Ousia Pharma ApS (this company)Board network connections
Board members of Ousia Pharma ApS also hold positions in 26 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeppe Ragnar Andersen | Board of Directors | 11 companiesMany roles |
| Mikael Søndergaard Thomsen | Board of Directors | 4 companies |
| Ian Rodney Laquian | Chairman | 3 companies |
| Morten Peltola Toft | Board of Directors | 3 companies |
| Christoffer Clemmensen | Management | 2 companies |
| Jonas Odgaard Petersen | Management | 2 companies |
| Anders Bue Klein | Management | 1 company |
Frequently asked questions
What is the CVR number of Ousia Pharma ApS?
Ousia Pharma ApS is registered with CVR / Virk under CVR 43055909.
What is the gross profit of Ousia Pharma ApS?
Ousia Pharma ApS reported a gross profit of -DKK 10.2m in 2025.
How many employees does Ousia Pharma ApS have?
Ousia Pharma ApS employs 8 people as of the latest annual report.
Who is the chairman of Ousia Pharma ApS?
Gaurav Gupta chairs the board of Ousia Pharma ApS, in role since 2026.
Where is Ousia Pharma ApS headquartered?
Ousia Pharma ApS's registered address is Ole Maaløes Vej 3.